Drug Profile

Lidocaine topical gel - Pharmanest

Alternative Names: SHACT

Latest Information Update: 20 Jan 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pharmanest
Class Acetanilides; Analgesics; Class Ib antiarrhythmics; Local anaesthetics; Non-opioid analgesics; Small molecules
Mechanism of Action Sodium channel antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II Procedural pain

Most Recent Events

29 May 2018 Lidocaine topical gel licensed to Acerus Pharmaceuticals in Canada for commercialisation
29 May 2018 Acerus Pharmaceuticals plans to launch lidocaine topical gel for Procedural pain in Canada in the first half of 2020
29 May 2018 Acerus Pharmaceuticals announces intention to submit NDA to the Health Canada for Procedural pain in the first half of 2019

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com